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We previously established a mechanism of negative regula-
tion of transforming growth factor  signaling mediated by the
nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymer-
ase 1 (PARP1) and the deribosylating enzyme poly-(ADP-
ribose) glycohydrolase (PARG), which dynamically regulate
ADP-ribosylation of Smad3 and Smad4, two central signaling
proteins of the pathway. Here we demonstrate that the bone
morphogenetic protein (BMP) pathway can also be regulated by
the opposing actions of PARP1 and PARG. PARG positively
contributes to BMP signaling and forms physical complexes
with Smad5 and Smad4. The positive role PARG plays during
BMP signaling can be neutralized by PARP1, as demonstrated
by experiments where PARG and PARP1 are simultaneously
silenced. In contrast to PARG, ectopic expression of PARP1
suppresses BMP signaling, whereas silencing of endogenous
PARP1 enhances signaling and BMP-induced differentiation.
The two major Smad proteins of the BMP pathway, Smad1 and
Smad5, interact with PARP1 and can be ADP-ribosylated in
vitro, whereas PARG causes deribosylation. The overall out-
come of this mode of regulation of BMP signal transduction
provides a fine-tuning mechanism based on the two major
enzymes that control cellular ADP-ribosylation.
The mechanisms of regulation of signaling pathways in the
TGF- family present significant complexity and are of para-
mount biological importance because they explain how these
pathways mediate physiological developmental processes and
how their activities malfunction under pathological conditions
(1–3). Among the 33 genes that are enlisted in the TGF- fam-
ily, the largest group is the bonemorphogenetic protein (BMP)4
subfamily. BMPs have established functions in the control of
tissue growth and differentiation acting during embryonic
development and in adulthood, as mediators of homeostatic
regulation (4–6). A hallmark function of many of the BMP
members is the differentiation of mesenchymal progenitors
into osteoblasts that will produce mature osteocytes and into
chondroblasts that will generate chondrocytes during the
development and remodeling of cartilage and bone (7). For
example, pluripotentmouse C2C12myoblasts can differentiate
into osteoblasts in response to many BMP ligands (8). During
osteoblast differentiation, genes such as ID1, the negative reg-
ulator of basic helix-loop-helix transcription factors, and ALP
(alkaline phosphatase) are transcriptionally induced by BMP
signaling (9, 10).
BMP signaling proceeds when ligands associate with their
type I and type II serine/threonine kinase receptors, whereby
the type II receptor kinase phosphorylates specific serine resi-
dues in the type I receptor and changes its conformation, lead-
ing to activation of the protein kinase in the type I receptor (11,
12). The activated type I receptor then phosphorylates Smad1,
Smad5, and Smad8, the three receptor-activated Smads
(R-Smads), in their C-terminal Ser-Xaa-Ser motifs, which then
associate with Smad4, the common mediator Smad (11, 12). In
this manner, activated complexes of R-Smad and Smad4 bind
to chromatin and regulate expression of target genes such as
ID1 and ALP. The ligand-bound oligomeric receptor complex
also activatesmembers of theMAPK family and their upstream
protein kinases, leading to a more integrated regulation of the
gene targets of the BMP pathway (12, 13).
The BMP pathway is controlled by a series of negative regu-
latory mechanisms that ensure proper duration, magnitude of
response, and differential kinetics depending on cell type and
biological context (1–3). Major negative regulators of BMP sig-
naling are the inhibitory Smads (I-Smads), Smad6 and Smad7,
whose genes directly respond to BMP-dependent Smad and
MAPK signaling, thus forming negative feedback loops (11, 12).
The I-Smads can interact with the BMP type I receptors and
competitively inhibit R-Smad phosphorylation, bind to Smad4,
block the transcriptional activity of Smad complexes, and also
recruit ubiquitin ligases to the type I receptors to promote their
internalization and degradation (1, 2).
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An alternative mechanism of negative control of TGF- sig-
naling pathways involves the post-translational modification of
Smad proteins by members of the intracellular ADP-ribosyl-
transferases structurally related to diphtheria toxin (ARTDs).
The best characterizedmember of the ARTD family is ARTD1,
also called poly-(ADP-ribose) polymerase-1 (PARP1) (14–16).
PARP1 can be activated during damage of DNA from chemical
agents or radiation and initiates theDNAdamage response that
mends the lesions produced on DNA. In addition, PARP1 can
ADP-ribosylate transcription and chromatin remodeling fac-
tors as well as histones, thus controlling the processes of tran-
scription and DNAmethylation (14, 15). PARP1 exhibits com-
plex regulation of its catalytic activity, and it can also ribosylate
itself in an autocatalytic manner (17). In addition, substrates
that are ADP-ribosylated by PARP1 also lose their ADP-ribose
modification by the sequential action of the enzyme poly-
(ADP-ribose) glycohydrolase (PARG) that cleaves poly-(ADP-
ribose) chains (18) and ADP-ribosylhydrolase 3 or macrodo-
main-containing proteins (e.g. MacroD1) that hydrolyze
mono-ADP-ribose frommodified substrates (19). Accordingly,
transcription is regulated by the balanced action of PARP1 and
PARG, which dynamically control the degree of ADP-ribosyla-
tion of chromatin-bound proteins (20). PARG is encoded by a
single gene, which gives rise to different isoforms. The longer
isoform is a nuclear 111-kDa protein, whereas the shorter 102-,
99-, and 60-kDa isoforms are predominantly cytoplasmic (21).
Smad3 and Smad4 binding to chromatin is inhibited after
ADP-ribosylation of their conserved N-terminal Mad homo-
logy 1 (MH1) domain (22). ADP-ribosylation of Smad3 and
Smad4 is catalyzed by the nuclear enzymes PARP1 and its sib-
ling PARP2, which associate with each other andwith the Smad
proteins in the nucleus (22, 23). ADP-ribose chains are
removed from Smad3 and Smad4 by the action of PARG, which
plays a positive regulatory role during TGF- signaling (23).
PARP1 acting in T lymphocytes participates in the transcrip-
tional repression of the receptor genes for TGF- (24). This
finding is in agreement with the binding of PARP1 in the pro-
moter sequences of the TGF- type II receptor gene, as ana-
lyzed in breast cancer cells (25). In agreement with the negative
regulation of TGF- signaling by PARP1, prostate tumors
developing in amouse carrying complete loss of functionmuta-
tion of PARP1 revealed enhanced epithelial-mesenchymal
transition caused by enhanced TGF- signaling in the prostate
carcinoma cells (26), which corroborates our original findings
whereby PARP1 impacted the mesenchymal transition of
mammary epithelial cells (22). On the other hand, the functions
of TGF- in vascular smooth muscle cells can be positively
affected by the activity of PARP1 (27). Despite this knowledge,
the impact of members of the ARTD family on BMP signaling
and BMP-specific Smad proteins remains unknown.
In this article, we address the question of regulation of BMP
signaling by ADP-ribosylation.We report that PARGpositively
regulates BMP signaling andosteoblast differentiation,whereas
PARP1 is a negative regulator. A corollary of this functional
importance of the two enzymes that control ADP-ribosylation
is the formation of protein complexes between R-Smads of the
BMP pathway and PARG and PARP1, as revealed by immuno-
precipitation and proximity ligation assays (PLA). In addition,
Smad1 and Smad5 can be ADP-ribosylated by PARP1, and
PARG removes the ADP-ribose chains from these Smads. The
new evidence establishes ADP-ribosylation as a widespread
regulatorymechanismof Smadproteins in theTGF- andBMP
families.
Experimental Procedures
Cell Culture and Transfections—HEK293T cells were cul-
tured according to protocols from the American Type Culture
Collection (LGC Standards AB, Borås, Sweden). Human
immortalized keratinocytes HaCaT were cultured as described
previously (28). C2C12 mouse myoblasts and C2C12 cells sta-
bly transfected with BMP-responsive element (BRE) construct
(named as C2C12-BRE-luc, a kind gift of P. ten Dijke, Leiden
UniversityMedical Center, Leiden, TheNetherlands) were cul-
tured in DMEM supplemented with 10% FBS and penicillin-
streptomycin. PARP1 knock-out mouse embryonic fibroblasts
(PARP1MEFs) were kindly provided by J. Ménissier-de Mur-
cia (University of Strasbourg, Strasbourg, France) (29). Tran-
sient transfections of cells were performed using FuGENE HD
(Roche) or Lipofectamine 2000 (Life Technologies) according
to the manufacturer’s protocols. siRNA oligonucleotides were
purchased from Dharmacon/Thermo Fischer Scientific, as
pools or individual pure molecules. Transfection of siRNA
oligonucleotides (20–25 nM) targeting human PARP1 (Dhar-
macon ONTARGETplus SMARTpool L-006656-00, individu-
als LU-006656-03, J-006656-06, siPARP1-1, and J-006656-08,
siPARP1-3), mouse PARP1 (Dharmacon ONTARGETplus
SMARTpool L-040023), human PARG (DharmaconON-TAR-
GETplus SMARTpool L-011488-00 individuals, LU-011488-
00, J-011488-05, siPARG-1, J-011488-07, and siPARG-3) or
non-targeting control pool (Dharmacon ONTARGETplus
Non-targeting pool D-001810-10), was performed using
siLentfect (Bio-Rad) transfection reagent. The cells were trans-
fected a single time or two times with a retransfection after 24 h
for totally 36 or 48 h and cultured in DMEM containing 0.1, 1,
or 10% FBS prior to stimulations and cell-based assays.
Growth Factors, Plasmids, and Other Reagents—Recombi-
nant mature human BMP7 was a gift from K. Sampath (Gen-
zyme-Sanofi). The dose used for BMP7 was 5 ng/ml, unless
indicated otherwise. Human mature BMP2 was a gift of H. F.
Lodish (Whitehead Institute for Biomedical Research, MIT,
Cambridge, MA). Recombinant mature human BMP4 and
TGF-1 were bought from PeproTech EC Ltd. (London, UK).
All growth factors were dissolved in vehicle consisting of 4 mM
HCl, 0.1% (w/v) fatty acid-free bovine serum albumin. The sec-
ond generation analog of dorsomorphin and highly selective
small molecule inhibitor of BMP type I receptors, dorsomor-
phin homolog 1, 4-[6-[4-(1-methylethoxy)phenyl]pyrazolo
[1,5-a]pyrimidin-3-yl]-quinoline, was synthesized by Ludwig
Cancer Research. The PARP1 inhibitors 3-aminobenzamide
(3-AB) and PJ34 were purchased from Sigma-Aldrich, and
Axxora, LLC/ENZOLife Sciences, respectively. H2O2 andCoo-
massie Brilliant Blue R250 were obtained fromMerck, whereas
-NAD was bought from Sigma-Aldrich. High purity recom-
binant PARP1 and PARG (20,000 units/mg, 0.1g/ml) isolated
from insect cells after baculoviral infection were bought from
Axxora, LLC/ENZO Life Sciences.
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TheWTBRE-luc reporter (BRE)2-luc and pCMV--galacto-
sidase used for normalization of transfection efficiency have
been described before (30). The mutant BRE-luc reporter
(BRE)2-luc#211 that shows very weak binding of Smad proteins
and is weakly activated by BMP signaling was kindly provided
by P. ten Dijke (Leiden University Medical Center, Leiden, The
Netherlands) (10). Expression vectors pcDNA3-FLAG-Smad1,
pcDNA3-FLAG-Smad3, pcDNA3-FLAG-Smad4, pcDNA3-
FLAG-Smad5, and pcDNA3-myc-PARP1 have also been previ-
ously described (22, 23, 30). Expression vector pCS2-Myc-
PARG and the empty vector pCS2 were kindly provided by P.
Caiafa (Sapienza University, Rome, Italy). Glutathione S-trans-
ferase fusions of Smads, GST-Smad1, and GST-Smad5 were
constructed by transfer from the pcDEF3 vector to pGEX-4T-1.
Smad1MH1 (residues 1–132)was amplifiedusingPfupolymer-
ase and was inserted into pGEX-4T-1 using the primer pair
5-CGCGGATCCAATGTGACAAGTTTATTTTCC-3 and
5-CCGCTCGAGTCAGCTTTCTACTCTCTTATAGTG-3.
GST-Smad1MH1mutants (K53A, K53R, and EELE to QQLQ)
were made by introducing a mutation in GST-Smad1 MH1 to
change Lys53 to Ala with double-stranded primer pair (only the
sense strand is shown, and the mutation is indicated by lower-
case and bold letters) 5-GCCATGGAGGAACTGGAAgcGG-
CCTTGAGCTGCCCAGGG-3, Lys53 to Arg using primer pair
5-GCCATGGAGGAACTGGAAAgGGCCTTGAGCTGCC-
CAGGG-3, and 49EELE to QQLQ using primer pair 5-GAA-
AAAGAAAGGTGCCATGcAGcAACGcAAAAGGCCTTG-
AGCTGC-3. All plasmids were sequenced (Eurofins, Uppsala,
Sweden) before use.
Antibodies—Mouse monoclonal anti-FLAG antibodies M2
(catalog no. F1804, lot no. SLB87188), and M5 (catalog no.
F4042, lot no. 105k6067) were purchased from Sigma-Aldrich
and used at 1:1,000 (v/v) dilution; the specificity of the anti-
FLAG antibodies was verified based on the recognition of the
appropriate transfected protein; the anti-FLAG antibody gave
rise to some background bands that were easy to discriminate
against. Rabbit polyclonal anti-PARP1 antibody (N-terminal)
used for PLAwithmouse anti-Smad1 (catalog no. 39559, lot no.
00909001) was purchased from Active Motif (La Hulpe, Bel-
gium) and used at 1:1,080 (v/v) dilution; the specificity of the
antibody was verified based on the electrophoretic mobility of
the protein and its loss after siRNA-mediated silencing.
Mouse monoclonal anti-PARP1 antibody used for immuno-
blotting (catalog no. 51-8114KC, lot no. 30826) was purchased
from BD Pharmingen/Transduction Laboratories and used at
1:2,000 (v/v) dilution; the specificity of the antibodywas verified
based on the electrophoretic mobility of the protein and its loss
after siRNA-mediated silencing. Mouse monoclonal anti-
PARG antibody, clone D8B10 (catalog no. MABS61, lot no.
2490688), was purchased from Merck/Millipore and used at
1:1,000 (v/v) dilution; the specificity of the antibodywas verified
based on the electrophoretic mobility of the isoforms of this
protein and their loss after siRNA-mediated silencing. Mouse
monoclonal anti-Smad4 (B8) antibody (catalog no. sc-7966, lot
no. E228) was purchased from Santa Cruz Inc. and used at
1:1,000 (v/v) dilution; the specificity of the antibodywas verified
based on the electrophoretic mobility of the protein, its loss
after siRNA-mediated silencing, and its co-precipitation with
R-Smads after TGF or BMP stimulation.Goat polyclonal anti-
Smad6/7 (N-19) antibody (catalog no. sc-7004, lot no. J130) was
purchased fromSantaCruz Inc. and used at 1:200 (v/v) dilution;
the specificity of the antibody was verified based on the electro-
phoretic mobility of the protein compared with overexpressed
Smad6 and Smad7 as molecular size marker and its loss after
siRNA-mediated silencing. Rabbit polyclonal anti-ID1 (Z-8)
antibody (catalog no. sc-428, lot no. B1306) was purchased
from Santa Cruz Inc. and used at 1:200 (v/v) dilution; the spec-
ificity of the antibody was verified based on the electrophoretic
mobility of the protein and its inducibility after BMP stimula-
tion. Mouse monoclonal anti--actin antibody (catalog no.
sc-69879, lot no. J1509) was purchased from Santa Cruz Inc.
and used at 1:1,000 (v/v) dilution; the specificity of the antibody
was verified based on the electrophoretic mobility of the pro-
tein appearing as single band. Mouse monoclonal anti--tubu-
lin antibody (catalog no. sc-8035, lot no. E2909) was purchased
from Santa Cruz Inc. and used at 1:1,000 (v/v) dilution; the
specificity of the antibodywas verified based on the electropho-
retic mobility of the protein appearing as single band. Rabbit
monoclonal anti-Smad1 antibody used for immunoblotting
(catalog no. 1649-1, lot no. YD020503) was purchased from
Epitomics (Burlingame, CA) and used at 1:1,000 (v/v) dilution;
the specificity of the antibody was verified based on the electro-
phoretic mobility of the protein, its loss after siRNA-mediated
silencing, and its co-precipitation with Smad4 after BMP stim-
ulation. Mouse monoclonal anti-Smad1 antibody used for
immunoprecipitation (catalog no. 913C1b, lot no. GR103403-5)
was purchased from Abcam (Cambridge, UK) and used at
1:1,000 (v/v) dilution; the specificity of the antibodywas verified
based on the electrophoretic mobility of the protein, its loss
after siRNA-mediated silencing, and its co-precipitation with
Smad4 after BMP stimulation. Rabbit polyclonal anti-Smad1
antibody used for immunoblotting (catalog no. ab33902, lot no.
GR179307-2) was purchased from Abcam (Cambridge, UK)
and used at 1:1,000 (v/v) dilution; the specificity of the antibody
was verified based on the electrophoretic mobility of the pro-
tein, its loss after siRNA-mediated silencing, and its co-precip-
itation with Smad4 after BMP stimulation. Rabbit monoclonal
anti-phospho-Smad1(Ser463/465)/Smad5 (Ser463/465)/Smad8
(Ser426/428) antibody (catalog no. 9511S, lot no. 8) was pur-
chased from Cell Signaling Technology (Danvers, MA) and
used at 1:1,000 (v/v) dilution; the specificity of the antibody was
verified based on the electrophoreticmobility of the protein, its
loss after siRNA-mediated silencing, and its inducibility after
BMP stimulation. Rabbit polyclonal anti-Smad5 antibody (cat-
alog no. 9517S, lot no. 4) was purchased from Cell Signaling
Technology (Danvers, MA) and used at 1:1,000 (v/v) dilution;
the specificity of the antibody was verified based on the electro-
phoretic mobility of the protein, its loss after siRNA-mediated
silencing, and its co-precipitation with Smad4 after BMP stim-
ulation.Mousemonoclonal anti-GAPDH antibody (catalog no.
AM4300, lot no. 0711003) was purchased from Ambion (Life
Technologies Corp., Foster City, CA) and used at 1:50,000 (v/v)
dilution; the specificity of the antibody was verified based on
the electrophoretic mobility of the protein appearing as single
band. Rabbit polyclonal anti-phospho-Smad1(Ser463/465) anti-
body was produced in house as previously described (28), and
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its IgG content was purified providing a final concentration of 2
g/ml; it was used at 1:5,000 (v/v) dilution; the specificity of the
antibody was verified based on the electrophoretic mobility of
the protein, its loss after siRNA-mediated silencing, and its
inducibility after BMP stimulation. Mouse monoclonal anti-
Myc (9E10) antibody was produced in house by culturing a
mouse hybridoma cell line as previously described (30) and its
IgG content was purified providing a final concentration of 2
g/ml; it was used at 1:10,000 (v/v) dilution; the specificity was
verified based on the recognition of the appropriate transfected
protein; the anti-Myc antibody gave rise to few background
bands thatwere easy to discriminate against. As secondary anti-
bodies we used donkey anti-goat antibody conjugated to HRP
(catalog no. sc-2020, lot no. H1715) purchased fromSanta Cruz
Inc. and used at 1:10,000 (v/v) dilution; goat anti-rabbit anti-
body conjugated toHRP (catalog no. 656120, lot no. 1576428A)
purchased from Invitrogen/Life Technologies and used at
1:40,000 (v/v) dilution; and goat anti-mouse antibody conju-
gated toHRP (catalog no. 626520, lot no. 1629505A) purchased
from Invitrogen/Life Technologies Corp. and used at 1:20,000
(v/v) dilution.
Immunoblotting—Total proteins from transfected and/or
stimulated HaCaT or HEK293T cells were extracted in a Non-
idet P-40 containing lysis buffer (20 mM Tris-HCl, pH 8.0, 1%
Nonidet P-40, 150 mM NaCl, 2 mM EDTA, and complete pro-
tease inhibitor mixture from Roche). Then lysates were heated
at 95 °C for 5 min and subjected to SDS-PAGE. The resolved
proteins were transferred to nitrocellulose using a Bio-Rad wet
or semidry transfer unit. The efficiency of immunoblotting and
equal loading of proteins was verified by staining of the nictro-
cellulose membrane with 0.1% (w/v) Ponceau S in acetic acid.
Upon incubation with primary antibodies and horseradish
peroxidase-conjugated secondary antibodies (see list above),
enhanced chemiluminescence assays were performed using the
Millipore kit (Merck/Millipore), and the immunoblots were
developed at ambient temperature andduring the first fewmin-
utes of the reaction that corresponded to the linear range of
light emission; immunoblots were exposed on x-ray films,
whichwere scanned and quantified byAIDA software (FujiFilm
Sweden, Stockholm, Sweden), or immunoblots were analyzed
in an automated imaging system (Bio-Rad) and the correspond-
ing software Quantity One. Digital image memory content was
reduced, and brightness contrast was adjusted using Adobe
Photoshop CS3.
Nucleocytoplasmic Fractionation—The nucleocytoplasmic
fractionation was performed using the CelLytic NuCLEAR
extraction kit from Sigma. Briefly, HaCaT cells were stimulated
as described in the figure legend and collected by trypsinization.
Hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2,
10 mM KCl, and complete protease inhibitor mixture from Sig-
ma-Aldrich) was added to the cells and incubated for 15min on
ice. Then cytoplasmic and nuclear fractions were isolated
according to the protocol. For immunoprecipitations from
nuclear fractions, the lysis buffer described above was used.
Co-immunoprecipitation Assays—HaCaT or HEK293T cells
were transfected and/or stimulated as indicated, and total pro-
teins were extracted in Nonidet P-40 lysis buffer, as described
above. Then the proteins of interest were immunoprecipitated
using specific antibodies. In case of endogenous co-immuno-
precipitations, antibodies were precoupled tomagnetic protein
A/G Dynabeads (Invitrogen/Life Technologies) and incubated
with the lysates overnight at 4 °C. For immunoprecipitation of
transfected proteins, antibodies preconjugated to magnetic
agarose beads (anti-mouse Dynabeads (M-280, catalog no.
11202D, lot no. 160461500) and anti-rabbit protein-A Dyna-
beads (catalog no. 10002D, lot no. 00315255) from Invitrogen/
Life Technologies were used and incubated with lysates for 2 h
at 4 °C. The immunocomplexes were washed four times in lysis
buffer, resolved by SDS-PAGE, and immunoblotted with anti-
bodies as described above.
GST Pulldown Assays—Plasmid DNA constructs encoding
GST fusion proteins were transformed into the BL21 strain of
Escherichia coli and BL21 expressing the GST fusion proteins
were inoculated at 37 °C. Then proteins were extracted from
bacteria using a Triton X-100 containing lysis buffer (50 mM
Tris-HCl, pH 7.5, 1 mM EDTA, 100mMNaCl, 5% glycerol, 0.5%
Triton X-100), supplemented with 1 mM DTT and protease
inhibitors, and incubated end over end at 4 °C, overnight, with
glutathione-Sepharose beads (catalog no. 17-5132-01, lot no.
10172617; GE Healthcare). The next day the GST-proteins
bound to beadswerewashed four times inGSTpulldownbuffer
(50mMTris-HCl, pH7.4, 100mMNaCl, 1%Nonidet P-40, 2mM
MgCl2) and dissolved in GST pulldown buffer supplemented
with protease inhibitors and sodium azide. Purified GST fusion
proteins conjugated to glutathione beads were added to total
cell lysates and incubated end over end at 4 °C for 2 h. The beads
were then washed four times using Nonidet P-40 lysis buffer
and before the last wash beads were transferred in new, clean
tubes. Samples were subjected to SDS-PAGE, followed by
immunoblotting as described above. Input of the GST fusion
proteins were loaded on separate gels and subjected to staining
by Coomassie Brilliant Blue and served as normalization
controls.
In Vitro ADP-ribosylation Assays—Newly prepared GST or
GST-Smad proteins were kept bound to glutathione beads and
incubated in 100 l of reaction buffer (100 mM Tris-HCl, pH 8,
10 mM MgCl2, 1 mM DTT), with or without 100 ng of PARP1
(Axxora, LLC/ENZO Life Sciences). Then 80 nM -NAD and
20 nM 32P--NAD (PerkinElmer) were added, and the reac-
tions were incubated for 30 min at 37 °C while shaking. At the
end of each reaction, beads bound to GST fusion proteins were
collected via centrifugation, followed by a quick double wash
with ice-cold Nonidet P-40 lysis buffer to remove excess radio-
active -NAD. Alternatively, a sample of the total reaction
was collected. Samples were then heated for 4 min at 95 °C in
sample buffer and loaded on gels. Gels were fixed, stained with
Coomassie Brilliant Blue, and dried before measuring radioac-
tivity in a Fuji-X Bio-Imager. The non-radioactive version of
the same assay was performed exactly in the same manner,
except that a total of 100 nM cold -NAD was included in the
reaction.
In Vitro De-ADP-ribosylation Assay—Freshly prepared GST
and GST-Smads were immobilized on glutathione beads with
100 l of reaction buffer (100 mM Tris-HCl, pH 8, 10 mM
MgCl2, 1 mMDTT) along with 100 ng of PARP1 and increasing
amounts of PARG (Axxora, LLC/ENZOLife Sciences). Then 80
PARP1 and PARG Regulate BMP Signaling
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nM -NAD and 20 nM 32P--NAD were added to the mix-
ture, and samples were incubated at 37 °C while shaking. After
30 min, beads were centrifuged at 4,000 rpm and washed three
times with ice-cold Nonidet P-40 lysis buffer to remove
unbound PARG, PARP1, and -NAD. Washed beads were
then mixed with sample buffer with -mercaptoethanol and
heated for 4 min at 95 °C and loaded on gels. Gels were then
fixed, stained with Coomassie Brilliant Blue, and dried to mea-
sure the radioactivity by a Fuji-X Bio-Imager.
Proximity Ligation Assay—HaCaT cells were washed with
PBS twice for 5 min with agitation and then permeabilized
with 0.2% Triton X-100 in PBS for 10min at room temperature
with agitation and washed with PBS again for 10 min. The cells
were blocked by incubating with Duolink II blocking solution
for 1 h at room temperature with agitation (80 rpm) and
removed prior to adding primary antibodies. The antibodies
were diluted in Duolink II antibody diluent 1:100, and the cells
were incubated overnight at 4 °C. The cells were washed three
times for 3 min with buffer A (Duolink; Olink Bioscience,
Uppsala, Sweden) prior to incubating with secondary probes
(Duolink II), diluted with Duolink II antibody diluent 1:5. The
cells were further incubated for 2 h at 37 °C with agitation (80
rpm), prior to washing three times, for 3 min with Buffer A.
Duolink ligation stock was diluted 1:5 in double-distilled water
and Duolink ligase was added to the ligation solution from the
previous step at a 1:40 dilution, and the mixture was vortexed.
Ligation solution was added to each sample, and the slides were
incubated in a preheated humidified chamber at 37 °C for 30
min. The slides were washed with buffer A twice for 2 min
under gentle agitation. Duolink amplification stock was diluted
1:5 in double-distilled water, and amplification solution was
added at 1:80 dilution while vortexing. Amplification solution
was added to each sample and the slides were incubated in a
preheated humidified chamber at 37 °C for 90 min and then
washed once with Buffer A for 5min at room temperature with
gentle agitation. Phalloidin 488 (1:40) and Hoechst (1:500)
(both purchased from Sigma-Aldrich) were added to PBS, and
the slides were incubated at room temperature for 10min prior
to two washes for 10 min with buffer B (Duolink II). The slides
were rinsed with double-distilled water and mounted with
Slowfade (Invitrogen/Life Technologies-Thermo Fischer Sci-
entific) mounting medium. Pictures were taken with a Zeiss
LSM-510 inverted confocal microscope equipped with a
Hamamatsu C4742-95 digital camera, using the Zeiss Plan-
neofluar 20/0.75 objective lens andphotographing at ambient
temperature without immersion oil. The DuolinkImageTool
software (Olink Bioscience) was used for image analysis and
signal quantification. Because of the antibody species specific-
ity requirement in PLA assays, a rabbit anti-PARP1 antibody
was combined with a mouse anti-Smad1 antibody (see Fig. 7,D
and E).
Real Time RT-PCR—Total RNA from HaCaT or HEK293T
cells was extracted using the RNeasy kit (Qiagen) according to
the protocol of the manufacturer. cDNAwas synthesized using
the iScript cDNA synthesis kit from Bio-Rad. Real-time PCR
was done using iTaq SYBR green supermix with ROX from
Bio-Rad in triplicate. Controls without reverse transcriptase
(RT) or without cDNA (water) were also included in every
quantitative PCR assay. Gene expression levels were deter-
mined by the comparative Ct method and using GAPDH or
HPRT1 (hypoxanthine phosphor-ribosyl transferase 1) as ref-
erence. Normalized mRNA expression levels are plotted in bar
graphs that represent average values from triplicate determina-
tions with standard deviations. Each independent experi-
ment was repeated at least three times. The primers used for
quantitative PCR amplification were: human PARP1 forward,
5-AAGCCCTAAAGGCTCAGAACG-3, reverse, 5-ACC-
ATGCCATCAGCTACTCGGT-3; human PARG forward,
5-GAAAGGGACGACTGGCAGCGG-3, reverse, 5-CCAA-
AGGCACCACAGCCCCA-3; human GAPDH forward, 5-
GGAGTCAACGGATTTGGTCGTA-3, reverse, 5-GGCA-
ACAATATCCACTTTACCA-3; human SMAD6 forward, 5-
GGCTCTGCGGGCCCGAATC-3, reverse, 5-GAGACATG-
CTGGCGTCTGAGAA-3; human SMAD7 forward, 5-
ACCCGATGGATTTTCTCAAACC-3, reverse, 5-GCCAG-
ATAATTCGTTCCCCCT-3; human ID1 forward, 5-GGA-
CGAGCAGCAGGTAAACG-3, reverse, 5-TGCTCACCTT-
GCGGTTCTG-3; and human HPRT1 forward, 5-GCTTCC-
TCCTCCTGAGCAGTC-3, reverse, 5-CACTAATCACG-
ACGCCAGGGCTGC-3.
Luciferase Assay—C2C12 cells stably transfected with the
BMP/Smad-responsive promoter reporter construct (BRE2-
luc) and PARP1/ MEFs were transfected with siRNAs or
plasmids prior to BMP7 stimulation for 7–18 h as indicated in
the figure legends. The activity of-galactosidase, derived from
a plasmid that was also stably transfected into C2C12 cells was
measured for normalization of the measurements. All cells
were lysed in lysis buffer containing 5 mM Tris-phosphate
buffer, pH 7.8, 2 mM DTT, 2 mM trans-1,2-diaminocyclo-
hexane-N,N,N,N-tetra-acetic acid, 5% glycerol, and 1%Triton
X-100. The -galactosidase assay was performed by mixing the
cell lysatewith 100mM sodiumphosphate, pH7.3, 1mMMgCl2,
50 mM -mercaptoethanol, and 0.67 mg/ml of o-nitrophenyl
-D-galactopyranoside, and the absorbance was monitored at
420 nm. Luciferase reporter assays were performed with the
enhanced firefly luciferase assay kit from either BD Phar-
Mingen, Inc. (Life Technologies) or from Biotium Inc. (Hay-
ward, CA), according to the manufacturers’ protocol. Normal-
ized promoter activity data are plotted in bar graphs that rep-
resent average values from triplicate determinations with
standard deviations. Each independent experiment was
repeated at least twice.
Alkaline Phosphatase Assay—C2C12 mouse myoblasts were
treated with BMP7 and/or transfected with siRNAs or plasmid
constructs as explained in the figures. The cells were washed
two times with PBS and then lysed in Triton X-100 containing
ALP buffer (1 mM MgCl2, 0.1 mM ZnCl2, 100 mM glycine, 0.1%
Triton X-100, pH 10.5). After the addition of ALP lysis buffer,
cells were incubated for 1 h on ice, on an orbital shaker; then
lysates were collected and centrifuged at 5,000 rpm for 4 min.
Then supernatant was collected and used for the reaction with
the alkaline phosphatase substrate p-nitrophenyl phosphate.
Samples with substrate were incubated at 37 °C for 30 min to
3 h until a yellow soluble pigment was produced. Triplicates
were used per each condition, and then absorbance was mea-
sured at 405 nm. Measurements were normalized to the total
PARP1 and PARG Regulate BMP Signaling
12710 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 24•JUNE 10, 2016
 at TSU
K
U
BA
 D
A
IG
A
K
U
 on July 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
amount of protein in each sample, measured with the bicin-
choninic acid protein assay kit (Pierce, Thermo Fischer Scien-
tific) according to the manufacturer’s protocol.
Statistical Analysis—The differences between mRNA levels
or reporter luciferase activity under control, gene specific
silencing, and protein overexpression conditions, were evalu-
ated statistically using a standard two-tailed t test for samples
with unequal variance and two-sample with equal variance,
respectively. Significance is reported at p 0.05 or at p 0.01.
The data are plotted in bar graphs that represent average values
from triplicate determinations with standard deviations. Each
experiment was repeated two to five times, which represents
biological repeats, and each of these included three technical
repeats.
Results
The PARG Glycohydrolase Has a Positive Contribution to
BMP Signaling—Influenced from the strong positive impact of
PARGonTGF- signaling (23), we examined the role of endog-
enous PARG on BMP signaling in various established cell mod-
els. Silencing of endogenous PARG in normal human HaCaT
keratinocytes, using a pool of four PARG-specific siRNAs sig-
nificantly reduced the induction of ID1 and Smad6 by BMP7
(Fig. 1A). These are two well established direct target genes of
BMP signaling in diverse cell types (9–11). The same results
were observed by analyzing ID1 and Smad7 protein expression
after BMP7 stimulation and PARG silencing in HaCaT cells
(Fig. 1B). Repeating these experiments with two additional,
individual siRNAs, siPARG-1 and siPARG-3, that potently
silenced the endogenous HaCaT PARG protein (Fig. 1C) led to
significant reduction of Smad6, Smad7, and ID1 induction by
BMP7 (Fig. 1, D and E). PARG overexpression in HEK293T
cells conversely enhanced Smad6mRNA (Fig. 2A) and ID1 pro-
tein induction (Fig. 2B) by BMP7. Attempts to perform the
PARG overexpression in the more physiological cell model of
HaCaT cells did not succeed because of low expression effi-
ciency of the PARG vector (unpublished results).
To assess a more general impact of PARG on BMP signaling
mediated by Smad proteins, we employed the mouse C2C12
pluripotent cell model that differentiates toward the osteoblas-
tic lineage upon stimulation with BMPs, including BMP7 (8).
To analyze the functional consequence of PARG overexpres-
sion on direct BMP-Smad transcriptional activity, we per-
formed transcriptional signaling assays in stably transfected
cells expressing a Smad1/5-specific promoter-reporter con-
struct, BRE2-luc, derived from the ID1 gene (10). Transfection
of PARG in the C2C12-BRE-luc cell model significantly
enhanced the BRE2-luc transcriptional activity in response to
BMP7 (Fig. 2, C and D). Analysis of receptor-phosphorylated
and total protein levels of Smad1 and Smad5 did not reveal any
significant changes after PARG overexpression, suggesting that
PARG acted by modulating the transcriptional activity of
Smads (Fig. 2D). All these experiments convincingly showed
that PARG is a positive regulator of BMP-mediated transcrip-
tional responses controlling different target genes of the BMP
signaling pathway.
PARG Interacts with Smad5—To start exploring how PARG
can regulate BMP signaling, we tested whether PARG could
form complexes with Smad proteins of the BMP pathway,
including Smad1, Smad5, and Smad4. Co-immunoprecipita-
tion experiments examined the association of Smad1, Smad5,
and Smad4 (as positive control) with PARG (Fig. 3A). Co-trans-
fection of HEK293T cells with Smad1, Smad5, and Smad4
revealed a complex of PARG with Smad5 and Smad4, whereas
Smad1 did not show interaction with PARG (Fig. 3A). Brief (30
min) stimulation with BMP7 significantly enhanced the com-
plexes between PARG and Smad5 or Smad4, whereas a Smad1-
PARG complex remained undetectable (Fig. 3A). In cells
co-transfected with all three Smads—Smad1, Smad5, and
Smad4—their complex with PARGwasmuch easier to observe
(Fig. 3B). These results were confirmed at the endogenous level
using theHaCaT keratinocytemodel (Fig. 3,C–E). Endogenous
Smad1 failed to form detectable complexes with endogenous
PARG (Fig. 3C). Endogenous Smad5 formed complexes that
were not further enhanced by BMP7 stimulation (Fig. 3D).
Endogenous Smad4 (positive control) also formed complexes
with endogenous PARG, and BMP7 stimulation could not
reveal any further enhancement of the association (Fig. 3E). To
identify in which subcellular compartment the PARG-Smad4
complexes are formed,we performed endogenous immunopre-
cipitation between PARG and Smad4 in nuclear and cytoplas-
mic HaCaT cell lysates. The PARG-Smad4 complexes were
observed only in the nuclear fraction. In addition, PARG also
interacted with PARP1 exclusively in the nucleus (Fig. 3F).
Thus, PARGcan associatewithBMPpathway Smads.However,
PARG seems to formmore stable complexes with Smad5 com-
pared with Smad1.
PARP1Opposes the Function of PARG inMediating BMP-de-
pendent Gene Responses—Because PARG acts on proteins that
are ADP-ribosylated and deribosylates them (18), we antici-
pated that the positive effects of PARGonBMP signalingwould
be counteracted by an ADP-ribosylating enzyme. We focused
on PARP1 because we previously established that PARP1ADP-
ribosylates and negatively regulates Smads of theTGF- signal-
ing pathway (22). We therefore silenced both PARG and
PARP1 simultaneously (Fig. 4, A and B) and analyzed target
gene expression after BMP7 stimulation (Fig. 4,C–E). Although
single PARG knockdown significantly reduced the inducible
expression of Smad6 and Smad7 by BMP7 stimulation, knock-
down of both PARG and PARP1 normalized the inducible
expression of these two genes (Fig. 4, C and D), suggesting that
PARG had an impact on ADP-ribosylationmediated by PARP1
andnot by other, independentADP-ribosylating enzymes. Sim-
ilar results were obtained by studying expression of Smad6 and
Smad7 proteins (Fig. 4E). Available antibodies make the analy-
sis of endogenous Smad6 and Smad7 proteins very difficult
because their levels are very low, and for this reason, the BMP7-
inducible levels of these two proteins appeared only slightly
higher than control; however, PARG knockdown reproducibly
reduced Smad6 and Smad7 levels after BMP7 stimulation,
whereas PARG/PARP1 double knockdown caused a relative
(but not complete) normalization of the protein levels after
BMP7 stimulation (Fig. 4E). The effects of the siRNAs on basal
levels of Smad6 and Smad7were less significant, suggesting that
PARG and PARP1 modulate the inducible expression of these
genes upon BMP signaling. These experiments demonstrated
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that PARG and PARP1 regulate BMP signaling co-dependently
and not by acting through independent, parallel mechanisms.
PARP1 Inhibits Transcriptional Signaling by BMP—The pre-
vious experiment suggested that similar to the TGF- signaling
pathway (22), PARP1might negatively regulate BMP signaling.
To test this possibility more rigorously, we performed gene
expression and transcriptional signaling assays after single
PARP1 interference, using a pool of four individual siRNAs.
Performing the knockdown of endogenous PARP1 in HaCaT
keratinocytes followed by stimulation of the cells with BMP7
and analysis of endogenous mRNA expression showed that
BMP-induced ID1 and Smad7 were further enhanced after
PARP1 silencing (Fig. 5A). Similar results were obtained when
ID1, Smad6 and Smad7 proteins were analyzed in HaCaT cells
stimulated with BMP7 (Fig. 5B). Silencing PARP1 enhanced
both basal and even more markedly the BMP7-inducible levels
PARP1 and PARG Regulate BMP Signaling
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FIGURE 1.Depletion of PARG inhibits BMP target gene expression. A, transient silencing of PARG in HaCaT cells, using specific siRNA targeting PARG
or non-targeting siRNA (siCtr) and in the presence or absence of 30 ng/ml BMP7 stimulation for 2 h, followed by qRT-PCR for ID1, SMAD6, and PARG
mRNAs. The bars represent the relative mRNA expression of the corresponding genes, normalized to the expression of the housekeeping gene GAPDH.
Mean values from triplicate determinations are shown in the graph, and standard deviation is presented with error bars. Asterisks indicate a statistically
significant difference at p  0.05. B, immunoblotting of lysates from HaCaT cells, transiently transfected with siRNA targeting PARG or non-targeting
siRNA (Ctr), with or without stimulation of 30 ng/ml BMP7 for 2 h. Specific antibodies for PARG, ID1, Smad7, phospho-Smad1/5/8, and -tubulin were
used for the detection of the corresponding protein levels. -Tubulin serves as a loading control, and phospho-Smad1/5/8 was used to evaluate the
efficiency of BMP7 stimulation. An asterisk indicates a nonspecific protein band. A representative immunoblot of four repeats is shown. Molecular size
markers in kDa are also marked. C, immunoblotting of lysates from HaCaT cells, transiently transfected with two individual siRNAs targeting PARG
(siPARG-1 and siPARG-3) or non-targeting siRNA (siCtr), with or without stimulation of 30 ng/ml BMP7 for 8 h. A specific antibody was used for the
detection of PARG protein levels. -Actin serves as a loading control. A representative immunoblot of three repeats is shown. Molecular size markers in
kDa are alsomarked.D, transient silencing of PARG in HaCaT cells, using two individual siRNAs targeting PARG (siPARG-1 and siPARG-3) or non-targeting
siRNA (siCtr) and in the presence or absence of 30 ng/ml BMP7 stimulation for 2 h, followed by qRT-PCR for SMAD6 and SMAD7mRNAs. The bars represent
the relative mRNA expression of the corresponding genes, normalized to the expression of the housekeeping gene HPRT1. The statistical analysis was
performed as explained in A. E, transient silencing of PARG in HaCaT cells, using two individual siRNAs targeting PARG (siPARG-1 and siPARG-3) or
non-targeting siRNA (siCtr) and in the presence or absence of 30 ng/ml BMP7 stimulation for 24 h, followed by qRT-PCR for PARG and ID1 mRNAs. The
data are presented as in A and D.
FIGURE 2. PARG positively contributes to BMP signaling. A, transient overexpression of PARG in HEK293T cells, using myc-PARG or the empty vector
(pCS2) plasmid DNA, in the absence or presence of 30 ng/ml BMP7 stimulation for 2 h, followed by qRT-PCR for SMAD6 and PARG mRNAs. The data are
presented as in Fig. 1A. An asterisk indicates a statistically significant difference at p 0.05. B, immunoblotting of lysates from HEK293T cells from the
experiment shown in A, transiently transfected with myc-PARG or the empty vector (pCS2) plasmid DNA and after stimulation with 30 ng/ml BMP7 or
vehicle control for 2 h. Specific antibodies for the detection of PARG, ID-1, and phospho-Smad1/5/8 protein (asterisk indicates a nonspecific protein
band) levels and -tubulin, which was used as a loading control for the assay. A representative immunoblot of three repeats is shown. Molecular size
markers in kDa are also marked. C, luciferase reporter assay in C2C12 BRE-luc cells transiently transfected with myc-PARG or the control empty vector
(pCS2) constructs without or with stimulation of cells with 30 ng/ml BMP7 for 7 h. Mean values from triplicate determinations normalized to -galac-
tosidase measurements along with the corresponding standard deviation are shown in the graph. An asterisk indicates a statistically significant
difference at p  0.05. D, immunoblotting of cell lysates from the experiment shown in C as a control for evaluating the transfection efficiency of the
indicated plasmids. Immunoblottingwas performed using specific antibodies for myc-PARG (anti-myc tag antibody), PARG, and phospho-Smad1/5/8 to
measure the efficiency of BMP7 stimulation and total Smad1 and Smad5 protein levels. An asterisk indicates nonspecific protein bands. A representative
immunoblot of three repeats is shown. Molecular size markers in kDa are also marked.
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of the three proteins that record the signaling activity of the
BMP pathway (Fig. 5B). Repeating these experiments with two
additional, individual siRNAs, siPARP1-1 and siPARP1-3,
which potently silenced endogenous HaCaT PARP1 mRNA
(Fig. 5C) and protein,5 led to significant enhancement of Smad6
induction by BMP7 (Fig. 5C). The potency of the individual
siRNAs was not as good as the potency of the pool of four
siRNAs (Fig. 5, compareAwithC). To strengthen this evidence,
we employed MEFs from the PARP1 knock-out mouse
(PARP1/ MEFs (29)) and reconstituted wild-type PARP1
together with the Smad1/5-specific ID1 promoter-reporter
construct, BRE2-luc (10). Reconstitution of wild-type PARP1
was sufficient to inhibit the BMP-specific reporter under both
basal and BMP7-stimulated conditions (Fig. 6A). As a negative
control, we analyzed a mutant BRE2-luc promoter-reporter
(Fig. 6A, BRE2-luc#211) that carriesmutations inmany (but not
all) of the Smad-binding elements of the promoter, and as a
result it shows weak inducibility of the reporter gene by BMP
signaling (10). Reconstitution of PARP1 into the knock-out
5 Y.Watanabe, P. Papoutsoglou, V.Maturi, Y. Tsubakihara,M. O.Hottiger, C.-H.
Heldin, and A. Moustakas, unpublished results.
FIGURE 3. PARG forms complexes with Smad5 and Smad4. A, immunoprecipitation (IP) of FLAG-Smad1, FLAG-Smad5, or FLAG-Smad4, followed by immu-
noblotting for myc-PARG in transiently transfected HEK293T cells with the indicated plasmids without (left panel) or with stimulation with 30 ng/ml BMP7 for
30 min (right panel). Immunoblots from total cell lysates (TCL) show the expression levels of the transfected proteins. A representative immunoblot of three
repeats is shown. Molecular size markers in kDa are also marked. B, immunoprecipitation of FLAG-Smad1/4/5 followed by immunoblot for myc-PARG in
transiently transfected HEK293T cells with the indicated plasmids. The expression levels of transfected proteins are presented in the corresponding immuno-
blots from TCL. A representative immunoblot of three repeats is shown. Molecular size markers in kDa are also marked. C, endogenous immunoprecipitation
of Smad1 followed by immunoblotting for endogenous PARG and Smad1 in cell lysates from HaCaT cells, in the absence or presence of stimulation with 30
ng/ml BMP7 for 30 min. Immunoprecipitation with nonspecific IgG served as a negative control. An asterisk shows the heavy Ig chain. Expression levels of
endogenous proteins are shown in TCL immunoblots. Because of the absence of PARG signal in the co-immunoprecipitation, two different exposures are
shown to clarify the identity of the void immunoblot. A representative immunoblot of three repeats is shown. Molecular size markers in kDa are also marked.
D, immunoprecipitation of endogenous PARG followed by immunoblotting for endogenous Smad5 and PARG in cell lysates from HaCaT cells, in the absence
or presence of stimulation with 30 ng/ml BMP7 for 30 min. Precipitation with nonspecific IgG served as a negative control. Expression levels of endogenous
PARG and Smad5 proteins are shown in TCL immunoblots. Phospho-Smad1/5/8 (p-Smad1/5/8) levels serve as control to evaluate the BMP7 stimulation. A
representative immunoblot of three repeats is shown. Molecular size markers in kDa are also marked. E, immunoprecipitation of endogenous PARG followed
by immunoblotting for endogenous Smad4andPARG in cell lysates fromHaCaT cells, in the absenceor presenceof stimulationwith 30ng/ml BMP7 for 30min.
Immunoprecipitationwith nonspecific IgG served as a negative control. Expression levels of endogenous PARG, Smad4, and phospho-Smad1/5/8 proteins are
shown in TCL immunoblots. A representative immunoblot of three repeats is shown.Molecular sizemarkers in kDa are alsomarked. F, immunoprecipitation of
endogenous PARG, followed by immunoblotting for endogenous Smad4, PARP1, and PARG from cytoplasmic or nuclear HaCaT extracts. The cells were
stimulatedwith 30 ng/ml BMP7 for 30min or left untreated, and immunoprecipitationwith a nonspecific IgGwas used as a negative control. Expression levels
of endogenous PARG, Smad4, and PARP1 in cytoplasmic or nuclear cell extracts are also shown. A representative immunoblot of three repeats is shown.
Molecular size markers in kDa are also marked.
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MEFs showed only marginal effects on reporter activity (Fig.
6A). PARP1 neither enhanced nor reduced significantly the
activity of this promoter-reporter, as expected, because the
promoter was only weakly induced (1.7-fold) by BMP7, com-
pared with the 18-fold inducibility of the wild-type promoter
(Fig. 6A). As a positive control we also analyzed a TGF--spe-
cific reporter, CAGA12-luc that is activated by Smad3 and
Smad4 and found that this reporter was potently inhibited by
wild-type PARP1 reconstitution in the knock-out cells (Fig. 6B).
Thus, PARP1 acts as a negative regulator of BMP signaling at
the level of Smad transcriptional function.
PARP1 Interacts with Smad1 and Smad5—To explore fur-
ther how PARP1 can negatively regulate BMP signaling, we
tested whether PARP1 could form complexes with Smad pro-
teins of the BMP pathway. N-terminally FLAG-tagged Smad1,
Smad3, Smad4, and Smad5 (Smad3 and Smad4 serving as pos-
itive controls) were transfected in HEK293T cells, and the for-
mation of complexes with endogenous PARP1 was analyzed by
co-immunoprecipitation assays (Fig. 7A). All four Smads
formed readily detectable and reproducible complexes with
endogenous PARP1. Note that in these experiments no stimu-
lation of cells with BMP ligand was performed, suggesting that
the transfected proteins acquire features of activated signaling
simply because of the transfection condition. Indeed, a much
stronger complex was detected when the cells were co-trans-
fected with either Smad1 and Smad4 or Smad5 and Smad4.5
This implies that the association of Smad1 or Smad5 with
PARP1 may require activation by the signaling pathway. As an
additional positive control, we treated cells with peroxide,
based on previous findings showing that brief activation of
PARP1 by peroxide treatment could lead to complexes between
PARP1 and Smad proteins of the TGF- pathway (22). Indeed,
both Smad1 and Smad5 formed complexes with PARP1 more
efficiently after peroxide treatment, as did the positive control
proteins, Smad3 and Smad4 (Fig. 7A).
We then used Smad1, Smad5, and Smad4 in fusion formwith
GST semipurified fromE. coli lysates on glutathione-Sepharose
and HEK293T cell extracts enriched in endogenous levels of
PARP1 (Fig. 7B).We found that PARP1 formed complexeswith
Smad1 and Smad5 that were as strong as the complex with
Smad4, which served as positive control, whereas no complex
was formed with GST protein alone (Fig. 7B).
FIGURE4.PARP1opposes the functionofPARGduring regulationofBMPtargetgeneexpression.A–D, transient silencingof (i) PARG; (ii) PARGandPARP1
simultaneously in HaCaT cells, using specific siRNAs targeting PARG or PARP1; or (iii) non-targeting siRNA (siCtr) and left unstimulated or stimulated with 30
ng/ml BMP7 for 2 h, followed by qRT-PCR for PARG (A), PARP1 (B), SMAD6 (C), and SMAD7 (D) mRNAs. Each siRNA for the double transfections was used at a
concentration of 20 nM (total concentration, 40 nM), and in the condition where only PARGwas silenced, the total siRNA concentration was adjusted by using
20 nM of siCtr siRNA. The data are presented as in Fig. 1A. Asterisks indicate a statistically significant difference at p 0.05. E, immunoblotting of lysates from
HaCaT cells, transiently transfected with siRNA targeting (i) PARG, (ii) PARG and PARP1 simultaneously, or (iii) non-targeting siRNA (Ctr), with or without
stimulationof 30ng/mlBMP7 for 2h. Specific antibodies for PARG, PARP1, Smad6, Smad7, and-actinwereused for thedetectionof the correspondingprotein
levels. -Actin served as a loading control. A representative immunoblot of three repeats is shown. Molecular size markers in kDa are also marked.
PARP1 and PARG Regulate BMP Signaling
JUNE 10, 2016•VOLUME 291•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 12715
 at TSU
K
U
BA
 D
A
IG
A
K
U
 on July 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
In agreement with the results of transfected or bacterially
expressed Smads, endogenous Smad1 from human HaCaT
keratinocytes co-immunoprecipitated with endogenous PARP1,
and the complex was further enhanced after a 30-min stimula-
tion of the cells with BMP7 (Fig. 7C). To analyze more carefully
the time-dependent formation of endogenous complexes
between PARP1 and Smad1, we performed PLA inHaCaT cells
using antibodies recognizing the specific endogenous proteins
(Fig. 7D). Complexes were recorded at all time points of the
time course experiment; however, the number of endogenous
complexes significantly rose after 10 min of stimulation with
BMP7 (Fig. 7,D andE). The detected protein complexes resided
mainly in the nuclei of the cells, but cytoplasmic complexes
were also recorded (Fig. 7E). Interestingly, upon BMP7 stimu-
lation, the number of cytoplasmic complexes decreased as the
number of nuclear complexes increased (Fig. 7E).
Finally, using a panel of four deletionmutants of Smad1 fused
to GST and similar to above HEK293T extracts enriched in
endogenous PARP1 revealed that PARP1 associated with the
N-terminal MH1 domain of Smad1, whereas the C-terminal
MH2 domain failed to exhibit detectable association (Fig. 7F).
We therefore conclude that PARP1 and Smad1 (and also
Smad5) interact with each other at the endogenous level, their
interaction can be enhanced by brief stimulation with BMP
ligand or peroxide, and the N-terminal MH1 domain of the
Smad protein seems to be responsible for the interaction.
PARP1 ADP-ribosylates and PARG Deribosylates BMP
Smads—We then asked whether the interaction between
Smad1 or Smad5 and PARP1 led to catalyticmodification of the
Smads via ADP-ribosylation (Fig. 8A). Using an in vitro ADP-
ribosylation assay based on recombinant proteins, we could
demonstrate robust ADP-ribosylation of both Smad1 and
Smad5 (Fig. 8A). The ADP-ribosylation of Smad1 and Smad5
was significantly weaker compared with Smad3 (compare the
radioactive ADP-ribose signal to the total amount of protein
used as substrate (Coomassie Brilliant Blue staining)) (Fig. 8A).
Note that because the ADP-ribosylation is performed using
GST fusions of Smads, the assay is performed as a pulldown,
which allows us to confirm that ADP-ribosylated PARP1 (auto-
catalyzed) is bound to its substrate, Smad1 or Smad5.
Including recombinant PARG in the ADP-ribosylation reac-
tion showed that PARG de-ADP-ribosylated both PARP1 and
FIGURE 5. Silencing of PARP1 enhances BMP-induced gene expression. A, transient silencing of PARP1, using specific siRNA targeting PARP1 or non-
targeting siRNA (Ctr) as a negative control in HaCaT cells, and in the presence or absence of 5 ng/ml BMP7 stimulation for 2 h, followed by qRT-PCR for PARP1,
ID1, and SMAD7mRNAs. Thedata arepresented as in Fig. 1A.Asterisks indicate a statistically significant difference atp0.05.B, immunoblottingof lysates from
HaCaT cells, transiently transfected with siRNA targeting PARP1 or non-targeting siRNA (Ctr), with or without stimulation of 30 ng/ml BMP7 for 24 h. Specific
antibodies for PARP1, ID1, Smad6, Smad7, and -actin were used for the detection of the corresponding protein levels. -Actin served as a loading control. A
representative immunoblot of three repeats is shown. Molecular size markers in kDa are also marked. C, transient silencing of PARP1, using two individual
siRNAs targeting PARP1 (siPARP1-1 and siPARP1-3) or non-targeting siRNA (Ctr) as negative control in HaCaT cells and in the presence or absence of 30 ng/ml
BMP7 stimulation for 2 h, followed by qRT-PCR for PARP1 and SMAD6 mRNAs. The data are presented as in A. Asterisks indicate a statistically significant
difference at p 0.05.
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Smad1 or Smad5 (Fig. 8B). Based on our previous study ofADP-
ribosylation of Smad3 and Smad4, we hypothesized that Smad1
was ADP-ribosylated at the homologous amino acid motif to
that in Smad3 (22). The conservedmotif has the form of EELEK
in Smad1 (Fig. 8C). This motif lies near the -hairpin structure
that binds directly to DNA and modulates the DNA binding
activity of Smad1 (Fig. 8F). Mutating Glu49, Glu50, and Glu52 to
Gln or the adjacent Lys53 to Arg did not perturb the association
of thesemutant Smad1MH1domainswith endogenous PARP1
fromHEK293T cells (Fig. 8C), confirming that pointmutations
in this -helical part of the MH1 domain did not perturb the
overall folding of the domain in a manner that would perturb
association with PARP1. The Glu49, Glu50, and Glu52 to Gln
mutations reduced the ADP-ribosylation of wild-type Smad1
MH1 domain by roughly 35% (Fig. 8D). Mutating Lys53 to Arg
also showed a corresponding 33% reduction in ADP-ribosyla-
tion relative to wild type. Mutating Lys53 to Ala resulted in a
more serious loss of ADP-ribosylation that was almost back-
ground (Fig. 8D). This mutant interacted well with endogenous
PARP1 (Fig. 8E) and with the recombinant PARP1 (Fig. 8E),
when comparedwith the other pointmutants and thewild-type
MH1 domain.We therefore conclude that Smad1 is ADP-ribo-
sylated in the short EELEK motif that precedes the -hairpin
domain (Fig. 8F), a site that is equivalent to the ADP-ribosyla-
tion site in Smad3 (22). Both Glu and Lys residues appear to be
acceptor sites for ribosylation in the MH1 domain of Smad1.
PARP1 Inhibition Has an Impact on Physiological Responses
to BMP Signaling during Differentiation—To confirm the func-
tional relevance of the above findings of Smad1/5 ADP-ribosy-
lation by PARP1, we relied on well established chemical inhib-
itors of this enzyme. In C2C12 pluripotent mesenchymal cells,
induction of alkaline phosphatase, an established marker of
osteoblastic differentiation (8), was strongly induced by BMP7
stimulation, and inhibition of PARP1 catalytic activity repro-
FIGURE 6. PARP1 down-regulates BMP signaling. A, luciferase reporter assay in PARP1/MEFs transiently transfected with myc-PARP1 or control empty
vector (pcDNA3) plasmid DNA and in the absence or presence of 10 ng/ml BMP7 for 18 h. The non-stimulated cells were treated with 0.5 M dorsomorphin
homolog 1, and the BMP7-stimulated cells were treated with DMSO. A wild-type BRE2-luciferase reporter (BRE2-luc WT) or a mutant BRE2-luciferase reporter
(BRE2-luc #211) and the-galactosidase constructswere also transiently co-transfected in these cells. The data are presented as in Fig. 2C. B, luciferase reporter
assay in PARP1/MEFs transiently transfectedwithmyc-PARP1 or a control empty vector (pcDNA3) plasmidDNAwith orwithout addition of 1 ng/ml TGF-1
for 18 h. The Smad-binding element or CAGA12-luciferase reporter construct (CAGA12-luc) and the -galactosidase constructs were also transiently co-
transfected into the cells. The data are presented as in Fig. 2C. Asterisks indicate a statistically significant difference at p 0.05.
PARP1 and PARG Regulate BMP Signaling
JUNE 10, 2016•VOLUME 291•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 12717
 at TSU
K
U
BA
 D
A
IG
A
K
U
 on July 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ducibly enhanced the BMP7-mediated osteoblast differentia-
tion (Fig. 9A). In a similar manner, catalytic inhibition of
PARP1 with two chemical inhibitors, 3-amino-benzamide and
PJ-34, also enhanced the BMP-dependent expression of ID1
and Smad7 (Fig. 9, B and C). Similar to the effects on endoge-
nous gene regulation, the inhibition of PARP1 catalytic activity
with the two chemical inhibitors, 3-amino-benzamide and
PJ-34, resulted in significantly enhanced transcriptional signal-
ing by BMP7 in the C2C12-BRE-luc cells (Fig. 9D). Replacing
the chemical inhibitor with genetic interference using the
PARP1 siRNA showed that silencing of endogenous PARP1 in
the C2C12-BRE-luc cells reproducibly enhanced BMP7 signal-
ing at the level of the BRE2-luc reporter activity (Fig. 9E).
Finally, the inverse experiment with overexpression of wild-
type PARP1 in the C2C12-BRE-luc cells followed by 18 h of
stimulation with BMP7 led to robust activation of the reporter,
and co-transfection of wild-type PARP1 reduced the reporter
activity almost to background levels (Fig. 9F). The same nega-
tive effect of PARP1 overexpression was also verified when the
transcriptional reporter was activated by BMP2 or BMP4
instead of BMP7 in the same cell model (Fig. 9, G and H). This
finding attests that the impact of PARP1 onBMP-specific Smad
signaling is independent from the specific ligand that activates
the Smad pathway. Our overall conclusion is that PARP1 and
PARG associate with BMP-specific Smad proteins and regulate
their transcriptional output in opposing ways, whereby PARP1
acts as a negative and PARG as a positive regulator of gene
expression downstream of BMP (Fig. 10).
FIGURE 7. PARP1 interacts with Smad1 and Smad5. A, immunoprecipitation (IP) of FLAG-Smad1, FLAG-Smad5, FLAG-Smad3, or FLAG-Smad4, followed by
immunoblotting for endogenous PARP1 in transiently transfectedHEK293T cellswith the indicatedplasmids and in the absence or presence of 10mMH2O2 for
10min, which induces PARP1 activity. Immunoblots from total cell lysates (TCL) show the expression levels of the corresponding transfected and endogenous
proteins. A representative immunoblot of three repeats is shown. Molecular size markers in kDa are also marked. B, pulldown assay with GST, GST-Smad1,
GST-Smad5, and GST-Smad4 semipurified from E. coli and endogenous PARP1 from HEK293T cells detected by immunoblotting; Coomassie Brilliant Blue
staining of the gel illustrates the amounts and quality of recombinant proteins. TCL is also immunoblotted as a marker of the expression level of endogenous
PARP1. A representative immunoblot of three repeated pulldown assays is shown. Molecular size markers in kDa are also marked. C, immunoprecipitation of
endogenous Smad1 followedby immunoblottingwith endogenousPARP1, Smad1, andp-Smad1 inHaCaT cells stimulatedwith vehicle or BMP7 (30ng/ml) for
30min. IgGprecipitation is shownas negative control. TCL shows the total level of endogenous proteins, p-Smad1,which serves as control for BMP stimulation
andGAPDH,which serves as protein loading control. A representative immunoblot of three repeats is shown.D, PLA inHaCaT cells without orwith stimulation
with 30ng/ml BMP7 for the indicated timeperiods, using specific Smad1andPARP1antibodies. Specific RCA signalsweredetected in thenuclei and cytoplasm
(significantly less compared with nuclear signals). PLA using a specific PARP1 antibody with a nonspecific mouse IgG (MIgG) antibody or a specific Smad1
antibody in combination with a nonspecific rabbit IgG (RIgG) antibody served as negative controls for the specificity of the PLA assays. Signals from PLA are
presented in red, DAPI staining for nuclei is in blue, and phalloidin for actin cytoskeleton staining is in green. A representative set of photomicrographs of three
repeats is shown. A bar indicates 10m. E, quantification of the results from the experiment shown inD using the DuolinkImage Tool, with data for respective
time points plotted as a histogram according to the number of RCA signals per cell, divided in cytoplasmic (green bars) and nuclear (red bars) signals. The
figureshowsarepresentativeexperiment fromthreerepeats.Asterisks indicateastatisticallysignificantdifferenceatp0.05.F,pulldownassaywithGST-fusedSmad1
domains semipurified fromE. coliandendogenousPARP1 fromHEK293Tcells detectedby immunoblotting;CoomassieBrilliantBlue stainingof thegel illustrates the
amounts andquality of recombinant proteins. TCL is also immunoblotted as amarker of the expression level of endogenousPARP1. A representative immunoblot of
three repeated pulldown assays is shown.Molecular sizemarkers in kDa are alsomarked.WB, Western blotting.
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Discussion
This study comes as a natural follow up of a series of recent
reports that established for the first time that enzymes of the
ADRT family, namely PARP1, PARP2, and PARG, regulate the
flow and biological outcome of signal transduction by TGF-
(22–25, 27). Because BMP pathways have distinct biological
and molecular functions, we focused on the regulation of BMP
signaling by PARP1 in the present paper. The current experi-
mental evidence presents a newmolecular regulatorymodel for
the BMP pathway (Fig. 10). Because BMP-specific Smad com-
plexes enter the nucleus and associate with chromatin to regu-
late gene expression, they also encounter the action of PARP1
and PARG. PARP1 ADP-ribosylates Smad1, Smad5, and
Smad4, whereas PARG de-ADP-ribosylates these Smads, and
this dynamic post-translational modification has an impact on
gene regulation and cell differentiation (Fig. 10).
Our previous work on Smad3 proposed that ADP-ribosyla-
tion of theMH1domainmotif negatively impactsDNAbinding
by Smad3 (22). A similarmechanismmay operate at the level of
BMP R-Smads. This is compatible with all effects measured on
FIGURE 8.PARP1ADP-ribosylates,whereas PARGde-ADP-ribosylates Smad1andSmad5.A, in vitroADP-ribosylation assay of Smad1, Smad5, Smad4, and
Smad3. GST-Smad proteins were incubated with 32P--NAD and recombinant PARP1. After glutathione-agarose pulldown, ADP-ribosylated GST-Smad1/5/
4/3 were imaged by autoradiography. The radioactive protein bands of PARP1 and GST-Smads aremarked. The lower panel shows GST-Smad proteins stained
with Coomassie Brilliant Blue after SDS-PAGE.M, molecular sizemarker. A representative autoradiogramof four assays is shown.Molecular sizemarkers in kDa
are also marked. B, in vitro de-PARylation of GST-Smad1 and GST-Smad5. PARG or vehicle were incubated with equal amounts of GST-Smad1/5, 32P--NAD,
and recombinant PARP1 for 30 min at 37 °C. ADP-ribosylated proteins were imaged by autoradiography. The radioactive protein bands of PARP1 and
GST-Smads aremarked. The lower panel shows total GST proteins stainedwith Coomassie Brilliant Blue.M, molecular sizemarker. A representative autoradio-
gram of five assays is shown. Molecular size markers in kDa are also marked. C, immunoblot of endogenous PARP1 from HEK293T cell extracts bound to the
indicated GST-Smad1 MH1 domain mutants. TCL shows the levels of endogenous PARP1. Total GST-Smad1 mutant proteins used for immunoblotting of
endogenous PARP1 are stainedwith Coomassie Brilliant Blue in themiddle panel. The Smad1 sequencemotif thatwasmutated (red letters) and that represents
a genuine ADP-ribosylation target sequence is shown in the bottom panel. A representative immunoblot of three repeats is shown. Molecular size markers in
kDa are alsomarked.D, in vitro ADP-ribosylation assay of GST-Smad1-MH1 domainmutants. Control GST, beads, WT-Smad1-MH1 domain, and threemutants
(as shown inC)were incubatedwith 32P--NADand recombinantPARP1.ADP-ribosylatedproteinswere imagedvia autoradiography. The radioactiveprotein
bandsof PARP1andGST-Smad1-MH1aremarked. TotalGSTproteinswere checkedbyCoomassie Brilliant Blue staining. Lane1/3WT indicates a reactionwhere
one-third of the GST-Smad1-MH1 protein was used compared with the WT lanes. A representative autoradiogram of two assays is shown. Molecular size
markers in kDa are also marked. E, immunoblot of recombinant PARP1 (20 ng) bound to the indicated GST-Smad1MH1 domainmutants. The experiment is a
repeat of the ribosylation assay of Fig. 8D, except that only cold-NADwas used during incubation, followed by pulldown and immunoblotting. On the side,
increasing amounts of recombinant PARP1 alongwith TCL fromHEK293T cells show the levels of recombinant PARP1used in the assay relative to endogenous
PARP1. Total GST-Smad1 mutant proteins checked by Coomassie Brilliant Blue staining, used for immunoblotting of recombinant PARP1. A representative
immunoblot of two repeats is shown. Molecular size markers in kDa are also marked. F, molecular model adapted to a detail from the crystal structure of two
Smad3MH1 domains bound to the Smad-binding DNA element (PDB code 1mhd). Shown is a ribbon diagram of the whole Smad3MH1 domain with colored
amino acids and the acceptor glutamate (red) and lysine (blue) residues drawn as stick and ball structures on the bottom side of the surface of the regulatory
-helix of one Smad3 MH1 subunit (white arrow). The -hairpin that contacts DNA is also indicated (white arrow).WB, Western blotting.
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the regulation of several endogenous genes that are established
targets of BMP signaling (Figs. 1, 2, 4, 5, and 9). PARG acts as a
positive and PARP1 as a negative regulator of gene expression
and osteoblast differentiation (Fig. 9). Themagnitude of effects
measured when endogenous PARP1 or PARG are inhibited
either via RNAi or via pharmacological intervention are repro-
ducible and significant but do not exhibit all-or-nothing behav-
ior. We interpret this finding as an indication that PARP1 and
PARG act as intermediate regulators of nuclear Smad activity
that is interwoven together with other site-specific enzymatic
activities, e.g. nuclear phosphorylation, dephosphorylation,
acetylation, monoubiquitylation, and polyubiquitylation, that
collectively regulate the activity of the chromatin-bound Smad
complexes. An example of such a BMP Smad co-factor that
attracts PARP family enzymes and contributes to the full bio-
logical outcome of BMP signaling is the knownmultizinc finger
transcriptional regulator OAZ (31). When PARP1 is bound to
OAZ, it positively promotes transcriptional regulation induced
by BMPs in P19 teratocarcinoma cells, suggesting that the pres-
ence or absence of OAZ in nuclear complexes of BMP Smads
may define the direction, magnitude, and specificity of regula-
tory events catalyzed by PARP1 (31). In futurework, it would be
interesting to examine the specificwindow in the time course of
nuclear Smad functions during which ADP-ribosylation
becomes most critical. The PLA analysis (Fig. 7, D and E) sug-
gests that this timewindowwill be relatively early; however, this
may differ from cell type to cell type and possibly even under
different pathophysiological conditions (27, 31).
By analyzing the interaction of Smad1 with PARG, we iden-
tified a relative selectivity of this association, whereby Smad1
seems to fail to form complexes with PARG, whereas Smad5
(and Smad4) form readily detectable complexes at the endoge-
nous level or upon overexpression (Fig. 3). At the moment, we
do not understand the reason behind this selectivity. In cells,
FIGURE 9. Inhibition of endogenous ADP-ribosylation activity promotes physiological responses to BMP7. A, alkaline phosphatase assay to assess
myoblast to osteoblast differentiation in C2C12 mouse cells, treated with 5 mM 3-AB and 3 M PJ34 (ADP-ribosylation inhibitors), and then stimulated with
vehicle or 300 ng/ml BMP7 for 3 days. Bars represent the relative alkaline phosphatase activity as a mean value from triplicate determinations and standard
deviation is shownwith error bars. Themeasurementswere normalized to total protein levels.Asterisks indicate a statistically significant differences atp 0.05.
B and C, qRT-PCR for ID1 (B) and SMAD7 (C) in lysates from C2C12 cells treated with the chemical ADP-ribosylation inhibitors 3-AB and PJ34 at 5 mM and 3 M
concentrations, respectively, or with vehicle (DMSO), 1 h prior to stimulation with 5 ng/ml BMP7 or vehicle for the indicated time periods. The data are
presented as in Fig. 1A. An asterisk indicates a statistically significant difference at p  0.05. D, luciferase reporter assay in mouse C1C12 myoblasts, stably
transfected with the BRE2-luciferase reporter construct (C2C12 BRE-luc cells) treated with the ADP-ribosylation inhibitors 5 mM 3-AB and 3 M PJ34 or with
vehicle (DMSO), 1 h prior to stimulation with 5 ng/ml BMP7 or vehicle for 18 h. The data are presented as in Fig. 2C. Asterisks indicate a statistically significant
difference at p 0.05. E, luciferase reporter assay in C2C12 BRE-luc cells transiently transfected with siRNA targeting PARP1 (siPARP1) or non-targeting siRNA
(siCtr) and in the presence or absence of stimulation with 5 ng/ml BMP7 for 18 h. The data are presented as in Fig. 1E. An asterisk indicates a statistically
significant difference at p 0.05. F, luciferase reporter assay in C2C12 BRE-luc cells upon transient transfection of increasing doses of myc-PARP1 or a control
empty vector (pcDNA3) and in the absence or presence of 30 ng/ml BMP7 for 18 h. The data are presented as in Fig. 2C. An asterisk indicates a statistically
significant difference at p 0.05. G, luciferase reporter assay in C2C12 BRE-luc cells upon transient transfection of myc-PARP1 () or a control empty vector
(pcDNA3,) and in the absence or presence BMP2 for 18 h. The data are presented as in Fig. 2C. An asterisk indicates a statistically significant difference at p
0.05, and double asterisks indicate a statistically significant difference at p 0.01.H, luciferase reporter assay in C2C12 BRE-luc cells upon transient transfection
of myc-PARP1 () or a control empty vector (pcDNA3, ) and in the absence or presence BMP4 for 18 h. The data are presented as in Fig. 2C. An asterisk
indicates a statistically significant difference at p 0.05, and double asterisks indicate a statistically significant difference at p 0.01.ALP, alkaline phosphatase.
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because BMP signaling organizes multi-Smad complexes con-
sisting of Smad1, Smad5, and Smad4, it is possible that the
presence of one Smad subunit suffices for bringing PARG into
the nuclear Smad complex.However, the selectivity observed in
the co-immunoprecipitation assays must have another struc-
tural and possibly biological reason that needs to be investi-
gated deeper. The investigation of the subcellular localization
of PARG-Smad4 complexes aimed to clarify whether nuclear or
cytoplasmic PARG isoforms participate in the formation of
protein complexes with Smad4 and revealed only nuclear local-
ization of the complexes. Taking into account that cytoplasmic
PARG isoforms have catalytic activity, the observation of the
nuclear PARG-Smad4 complex possibly implies a rapid
de-ADP-ribosylation of Smad4, concomitant to its ADP-ribo-
sylation by PARP1.
The BMP-specific Smad1 and Smad5 form complexes with
PARP1 (Fig. 7). The MH1 domain of Smad1, similar to Smad3
andSmad4, provides the specificity for this interaction (Fig. 7F),
which is compatible with the fact that specific amino acids in
the MH1 domain become ADP-ribosylated by PARP1 (Fig. 8).
On the other hand, it is also possible that the Smad1 MH1
domain association with DNA regulates the interaction with
PARP1 and the subsequent ADP-ribosylation. It is of course
formally possible that PARP1 meets Smad1 prior to its associ-
ation with DNA; however, growing evidence from genome-
wide screens and deeper understanding of the functions of
chromatin regulators like PARP1 suggest that most of these
intermolecular associations and post-translational modifica-
tions occur on chromatin. Possible development of in situ PLA
coupled with fluorescent in situ hybridization technology (32)
may allow us to resolve this interesting question. Inmany of the
interaction assays, we were able to monitor Smad1-PARP1
complexes in the absence of BMP stimulation; however, BMP
stimulation or PARP1 activation by means of peroxide treat-
ment both significantly enhanced the abundance of complexes
formed (Fig. 7). Treating cells with a brief pulse of peroxide is
sufficient to activate endogenous PARP1 and very quickly this
leads to an enhanced complexwith Smad1 and Smad5 (Fig. 7A).
Although it is possible that peroxide might affect other molec-
ular players in the cell (e.g. protein phosphatases), our collective
evidence supports a PARP1-dependent role that enhances the
association between Smads and PARP1. Using PLA, we identi-
fied a rapid kinetic profile of Smad1-PARP1 complex formation
at the endogenous level (Fig. 7,D and E). Although themajority
of complexesmeasuredwere nuclear, PLA also revealed endog-
enous cytoplasmic complexes (Fig. 7E). Smad1 constantly shut-
tles in and out of the nucleus, whereas PARP1 shows more
stable association with the nuclear compartment. Whether
Smad1 carries PARP1 at different subcellular compartments at
this stage is speculative and requires further deeper investiga-
tion. Similarly, the exact meaning of the dynamic changes of
Smad1-PARP1 complexes over time of BMP signaling remains
open to future analysis.
FIGURE 10. PARP1 and PARGmodulate Smad1 activity during BMP signaling.Amodel shows the BMP ligand activating cell surface receptors II and I, with
the latter phosphorylating Smad1, Smad5, and Smad8, facilitating oligomerizationwith Smad4 to enter the nucleus through a nuclear pore. The nuclear Smad
complex associates with transcription factors, co-activators or co-repressors on chromatin to regulate target genes such as ID1, SMAD6, and SMAD7. The
ADP-ribosylating enzyme PARP1 interacts with the nuclear Smad complex. With -NAD as a donor, PARP1 attaches ADP-ribose chains (of n size, [ADPr]n) on
itself (not shown) and on to the Smad complex to assist its dissociation fromDNA or inhibit association with DNA (Smad proteins away fromDNA). PARG that
has affinity toward ADP-ribose chain promotes de-ADP-ribosylation resulting in mono-ADP-ribose chains on the Smad complex (not verified experimentally
and not shown for simplicity) and a pool (n) of ADP-ribose, thus facilitating enhanced binding of the Smad complex to DNA. For simplicity, the figure
emphasizes Smad1 ADP-ribosylation. The extracellular matrix (ECM), cytoplasmic, and nuclear cell compartments are highlighted.
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By analyzing the ADP-ribosylation of Smad1 and Smad5 in
vitro, we found that both R-Smads can be modified by PARP1,
and PARG can remove ADP-ribose chains from these Smads
(Fig. 8). Themotif identified as a putative ADP-ribosylation site
in Smad1, EELEK, is well conserved among all Smad proteins
and resides in theMH1 domain and juxtaposes the-hairpin of
the MH1 domain that binds to DNA (1–3). Mutating specific
glutamate residues indicated a significant decrease of ADP-ri-
bosylation but not complete loss (Fig. 8D). Mutation of Lys53 to
Arg decreased the ADP-ribosylation efficiency, but its muta-
tion to Ala failed to show ADP-ribosylation (Fig. 8D). The var-
ious MH1 domain point mutants employed here were synthe-
sized and semipurified from E. coli (Fig. 8, A–E) and were
capable of associating with endogenous (Fig. 8C) and recombi-
nant (Fig. 8E) PARP1, suggesting that the mutations did not
alter folding of the MH1 domain. Thus, Smad1 (and by extrap-
olation Smad5) may accept ADP-ribose units on the glutamate
or lysine residues of the conserved EELEK motif within the
MH1 domain, which is compatible with the general knowledge
of ADP-ribosylation sites (17). PARG was capable of reducing
the level of ADP-ribosylation of the Smad1 MH1 domain (Fig.
8B) but did not completely remove ADP-ribose from Smad1/5,
even after prolonged incubation with PARG (Fig. 8B). Possibly,
members of the ADP-ribosylhydrolase andmacrodomain-con-
taining protein families (19) may cooperate with PARG to
achieve complete removal of ADP-ribosyl chains from the
BMP-specific R-Smads.
We have established ADP-ribosylation and the actions of
PARP1 and PARG as important regulatory steps in the progres-
sion and execution of physiological BMP signaling. These new
findings also propose that PARP1 and PARG chemical modu-
lators (e.g. inhibitors) (18, 33) could be of potential use to reg-
ulate the potency of the BMP pathways at will. This can be of
importance for the control of BMP signaling activity in the
many pathological cases where these pathways malfunction
such as hypertension and cancer or various rare syndromes (11,
12). The recent finding that TGF- sensitizes breast cancer
cells to lethality in response to PARP1 inhibitors is fully com-
patible with our proposal (34). We therefore conclude that this
investigation provides the necessary basic background based on
which such future explorations can be founded.
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